Literature DB >> 21041375

Bevacizumab-induced regression of anaplastic meningioma.

M J A Puchner, V H Hans1, A Harati2, F Lohmann2, M Glas3, U Herrlinger4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041375     DOI： 10.1093/annonc/mdq634

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Authors:  Emil Lou; Ashley L Sumrall; Scott Turner; Katherine B Peters; Annick Desjardins; James J Vredenburgh; Roger E McLendon; James E Herndon; Frances McSherry; Julie Norfleet; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

2.  Antiangiogenic treatment of meningiomas.

Authors:  Matthias Preusser; Christine Marosi
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

Review 3.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

Review 4.  Pathogenesis of peri-tumoral edema in intracranial meningiomas.

Authors:  Moncef Berhouma; Timothee Jacquesson; Emmanuel Jouanneau; François Cotton
Journal:  Neurosurg Rev       Date:  2017-08-24       Impact factor: 3.042

5.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

6.  Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Authors:  Julia Furtner; Veronika Schöpf; Katharina Seystahl; Emilie Le Rhun; Roberta Rudà; Ulrich Roelcke; Susanne Koeppen; Anna Sophie Berghoff; Christine Marosi; Paul Clement; Marina Faedi; Colin Watts; Wolfgang Wick; Riccardo Soffietti; Michael Weller; Matthias Preusser
Journal:  Neuro Oncol       Date:  2015-09-09       Impact factor: 12.300

7.  Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study.

Authors:  J P Boström; M Seifert; S Greschus; N Schäfer; M Glas; G Lammering; U Herrlinger
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

8.  Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Authors:  Yongli Ji; Cathryn Rankin; Steven Grunberg; Andy E Sherrod; Jamshid Ahmadi; Jeannette J Townsend; Lynn G Feun; Ruth K Fredericks; Christy A Russell; Fairooz F Kabbinavar; Keith J Stelzer; Anne Schott; Claire Verschraegen
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

9.  Stereotactic radiosurgery for WHO II and III meningiomas: analysis of long-term clinical and radiographic outcomes.

Authors:  Brian J Williams; David J Salvetti; Robert M Starke; Chun Po Yen; Jason P Sheehan
Journal:  J Radiosurg SBRT       Date:  2013

10.  Regression of Intracranial Meningiomas Following Treatment with Cabozantinib.

Authors:  Rupesh Kotecha; Raees Tonse; Haley Appel; Yazmin Odia; Ritesh R Kotecha; Guilherme Rabinowits; Minesh P Mehta
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.